Epidemiology and mycology of candidemia in non-oncological medical intensive care unit patients in a tertiary center in the united states: Overall analysis and comparison between non-COVID-19 and COVID-19 cases

Mycoses. 2021 Feb 20. doi: 10.1111/myc.13258. Online ahead of print.


BACKGROUND: The epidemiology and mycology of invasive candidiasis in the ICU is well-described in certain types of critically ill patients but not in others. One population that has been scarcely studied is non-neutropenic patients admitted specifically to medical ICUs. Even less is known about the broader category of medical ICU patients without active oncological disease. This group constitutes a very large share of the patients requiring critical care across the globe, especially in the era of the SARS-CoV-2 pandemic.

PATIENTS/METHODS: We analyzed medical ICU candidemia episodes that occurred in non-oncological patients in our tertiary academic center in the United States from May 2014 to October 2020 to determine the incidence and species distribution of the associated isolates. We then separately considered non-COVID-19 and COVID-19 cases and compared their characteristics.

RESULTS: In the non-COVID-19 group, there were 38 cases for an incidence of 1.1% and rate of 11/1000 admissions. In the COVID-19 group, there were 12 cases for an incidence of 5.1% and rate of 51/1000 admissions. In the entire sample, as well as separately in the non-COVID-19 and COVID-19 groups, Candida albicans accounted for a minority of isolates. Compared to non-COVID-19 patients with candidemia, COVID-19 patients had lower ICU admission SOFA score but longer ICU length of stay and central venous catheter dwell time at candidemia detection.

CONCLUSION: This study provides valuable insight into the incidence and species distribution of candidemia cases occurring in non-oncological critically ill patients and identifies informative differences between non-COVID-19 and COVID-19 patients.

PMID:33608923 | DOI:10.1111/myc.13258